Dimensional Fund Advisors LP Has $49 Million Stake in Organon & Co. (NYSE:OGN)

Dimensional Fund Advisors LP raised its holdings in Organon & Co. (NYSE:OGN - Free Report) by 23.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 3,284,408 shares of the company's stock after buying an additional 629,191 shares during the period. Dimensional Fund Advisors LP owned 1.28% of Organon & Co. worth $48,999,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Freedom Investment Management Inc. increased its position in shares of Organon & Co. by 12.0% in the fourth quarter. Freedom Investment Management Inc. now owns 11,344 shares of the company's stock valued at $169,000 after acquiring an additional 1,218 shares during the last quarter. GeoWealth Management LLC acquired a new position in shares of Organon & Co. during the 4th quarter worth approximately $41,000. Commerce Bank raised its stake in shares of Organon & Co. by 10.1% during the 4th quarter. Commerce Bank now owns 13,398 shares of the company's stock worth $200,000 after purchasing an additional 1,230 shares in the last quarter. Canada Pension Plan Investment Board boosted its holdings in shares of Organon & Co. by 465.8% in the 4th quarter. Canada Pension Plan Investment Board now owns 21,500 shares of the company's stock valued at $321,000 after buying an additional 17,700 shares during the last quarter. Finally, Advent Capital Management DE grew its stake in shares of Organon & Co. by 60.0% in the fourth quarter. Advent Capital Management DE now owns 200,000 shares of the company's stock valued at $2,984,000 after buying an additional 75,000 shares in the last quarter. 77.43% of the stock is currently owned by institutional investors and hedge funds.

Organon & Co. Trading Up 1.6 %

Shares of OGN stock opened at $9.60 on Friday. Organon & Co. has a 12-month low of $9.18 and a 12-month high of $23.10. The company has a market capitalization of $2.50 billion, a PE ratio of 2.88, a price-to-earnings-growth ratio of 0.90 and a beta of 0.73. The firm has a 50 day moving average price of $13.46 and a two-hundred day moving average price of $14.96. The company has a quick ratio of 1.21, a current ratio of 1.70 and a debt-to-equity ratio of 17.73.

Organon & Co. (NYSE:OGN - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The company reported $1.02 earnings per share for the quarter, topping the consensus estimate of $0.89 by $0.13. Organon & Co. had a return on equity of 431.62% and a net margin of 13.49%. The business had revenue of $1.51 billion during the quarter, compared to analysts' expectations of $1.53 billion. During the same period last year, the firm posted $1.22 EPS. The firm's revenue for the quarter was down 6.7% compared to the same quarter last year. As a group, analysts predict that Organon & Co. will post 3.68 earnings per share for the current year.

Organon & Co. Cuts Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, June 12th. Investors of record on Monday, May 12th will be paid a $0.02 dividend. The ex-dividend date is Monday, May 12th. This represents a $0.08 annualized dividend and a dividend yield of 0.83%. Organon & Co.'s dividend payout ratio (DPR) is presently 33.63%.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. Evercore ISI lowered shares of Organon & Co. from an "outperform" rating to an "inline" rating in a research report on Friday. Morgan Stanley cut their target price on shares of Organon & Co. from $16.00 to $15.00 and set an "equal weight" rating for the company in a research note on Wednesday, April 9th. TD Cowen raised Organon & Co. to a "hold" rating in a research report on Wednesday, January 15th. Finally, Barclays cut their price objective on Organon & Co. from $26.00 to $24.00 and set an "overweight" rating for the company in a research report on Friday, February 14th. One analyst has rated the stock with a sell rating, three have given a hold rating and one has assigned a buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Hold" and an average target price of $19.75.

Organon & Co. Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.